Brain Tumors
BOLD Asynchrony
BOLD asynchrony elucidates tumor burden in IDH-mutated gliomas (Neuro-Oncology, 2022) – BOLD asynchrony is proportional to tumor burden in IDH-mutated gliomas, is more sensitive to tumor burden than standard-of-care MR imaging, and can be used for neurosurgical planning of extent of resection.
Asynchrony in peritumoral resting-state blood oxygen level–dependent fMRI predicts meningioma grade and invasion (American Journal of Neuroradiology, 2021) – High-grade infiltrating meningioma disrupts neurovascular coupling which results in elevated BOLD asynchrony.
Glioma-induced alterations in neuronal activity and neurovascular coupling during disease progression (Cell Reports, 2020) – Infiltrating tumor disrupts neurovascular coupling in a tumor mouse model.
Extent of BOLD vascular dysregulation is greater in diffuse gliomas without isocitrate dehydrogenase 1 R132H mutation (Radiology, 2018) – The spatial distribution of BOLD asynchrony differs between IDH1 wild-type and IDH1 mutated gliomas. BOLD asynchrony extends further beyond visible tumor in IDH1 wild-type tumors suggesting a greater degree of infiltration. Gross total resection of IDH1 mutated tumors results in 5-10% of residual tumor. Gross total resection of IDH1 wild type tumors results in ~40% of residual tumor, suggesting one of the main factors in the high rate of recurrence in IDH1 wild-type gliomas.
Local glioma cells are associated with vascular dysregulation (American Journal of Neuroradiology, 2018) – The BOLD asynchrony signal is directly related to tumor burden indicating that infiltrating glioma cells disrupt neurovascular coupling.
Glioblastoma induces vascular dysregulation in non-enhancing peritumoral regions in humans (American Journal of Roentgenology, 2016) – A description of the methodology behind the BOLD asynchrony technique for detecting non-enhancing glioma.
Misc
Timing of Planning Magnetic Resonance Imaging and Patient Selection for Adaptive Radiation Therapy in Newly Diagnosed High-Grade Glioma (Red Journal/IJROBP, 2025) – Radiation therapy planning for high-grade glioma typically relies on a single postoperative MRI, assuming stable tumor and brain architecture throughout treatment. Though the gross tumor volume and surrounding tissues can shift after surgery and throughout RT, its rate of change, predictors of the movement magnitude, and impact on different dosing strategies are not well understood. This study uses meta-analysis and prospective MRI data to optimize MRI timing and identify patients who may benefit from adaptive RT (ART). We provide recommendations for clinical decision-making.
Biologically informed deep neural networks provide quantitative assessment of intratumoral heterogeneity in post treatment glioblastoma (NPJ Digital Medicine, 2024) – We developed a biologically-informed neural network (BioNet) to predict regional distributions of proliferating tumor and reactive/inflammatory cells in recurrent GBM.
MGMT promoter methylation predicts overall survival after chemotherapy for 1p/19q-codeleted gliomas (Clinical Cancer Research, 2023) – MGMT promoter status should be considered as a stratification factor in future clinical trials of 1p/19q-codeleted gliomas that use OS as an endpoint.
MGMT promoter methylation predicts survival in low grade and anaplastic gliomas after alkylating chemotherapy (JAMA Oncology, 2023) – MGMT promoter methylation may be considered as a stratification factor in future clinical trials of patients with IDH-wildtype and IDH-mutant/codeleted tumors and may affect future versions of the WHO classification scheme for gliomas.
MR elastography identifies regions of extracellular matrix reorganization associated with shorter survival in glioblastoma patients (Neuro-Oncology Advances, 2023) – MR Elastography can provide unique information on intratumoral heterogeneity. The gene expression signal associated with higher stiffness is related to active extracellular reorganization and is negatively correlated with survival.
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial (Lancet Oncology, 2022) – Convection-enhanced delivery of topotecan destroys proliferating tumor cells without destroying neurons.
A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies (American Journal of Neuroradiology, 2018)
Imaging genetic heterogeneity in glioblastoma and other glial tumors: review of current methods and future directions (American Journal of Roentgenology, 2018)
Deep-learning convolutional neural networks accurately classify genetic mutations in gliomas (American Journal of Neuroradiology, 2018)
Sodium fluorescein facilitates guided sampling of diagnostic tumor tissue in non-enhancing gliomas (Neurosurgery, 2017)